TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06630728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Content Cigars
Description: Participants will complete 3 smoking sessions using a different product each session to examine each product's abuse liability

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal nicotine content cigar
Description: Participants will smoke a normal nicotine content filtered little cigar

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual brand cigar
Description: Participants will smoke their usual brand filtered little cigar
Study: NCT06630065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fMRI with emotional task and pupillometry
Description: Anatomical and functional magnetic resonance imaging (fMRI) imaging sequences with pupillometry (\~90 min)~A functional sequence - Task (\~20min):~* Emotional task in fMRI: Instructions: simply look images, then evaluate the emotions triggered at the end of each block; rating on a valence and intensity scale and intensity (arousal) scale.~* Experimental conditions: positive, negative and neutral~* Paradigm: block validated image banks: IAPS, GAPED, EMOPICS, OASIS, etc. Pupillometry: In order to collect objective data on emotional bias, we will use pupillometry (or eye-tracking) during functional MRI sequences.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: fMRI with emotional task and pupillometry
Description: Anatomical and functional magnetic resonance imaging (fMRI) imaging sequences with pupillometry (\~90 min)~A functional sequence - Task (\~20min):~* Emotional task in fMRI: Instructions: simply look images, then evaluate the emotions triggered at the end of each block; rating on a valence and intensity scale and intensity (arousal) scale.~* Experimental conditions: positive, negative and neutral~* Paradigm: block validated image banks: IAPS, GAPED, EMOPICS, OASIS, etc. Pupillometry: In order to collect objective data on emotional bias, we will use pupillometry (or eye-tracking) during functional MRI sequences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral task with emotional facial expressions
Description: Description of the recognized emotion joy - sadness. Test to assess the hedonic value of an olfactory stimulus (10 min)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral task with emotional facial expressions
Description: Description of the recognized emotion joy - sadness. Test to assess the hedonic value of an olfactory stimulus (10 min)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Biological investigation
Description: Standard biological assessment, immuno-inflammatory profile and the association of 8 mRNA editing variants
Study: NCT06471465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Drug: corticosteroids IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Drug: corticosteroids IV
Study: NCT06630065

Intervention type: GENETIC
Group type: OTHER
Intervention: Biological investigation
Description: Standard biological assessment, immuno-inflammatory profile and the association of 8 mRNA editing variants
Study: NCT06629805

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aureobasidium pullulans produced β-glucan
Description: Aureobasidium pullulans produced β-glucan 1,000 mg/day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1,000 mg/day for 12 weeks
Study: NCT06632145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cog Fun Ageing intervention
Description: Cog Fun Ageing is a group-based occupation-centered intervention aimed at promoting positive occupational experiences despite cognitive challenges in day to day life. The intervention includes 14 weekly 120-minute group sessions led by experienced occupational therapists. Sessions incorporate learning about the bio-psycho-social factors of SCD and strategies to manage and cope with occupational challenges resulting from SCD.
Study: NCT06714396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QRL-101
Description: Single doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single doses of compartor placebo will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
Study: NCT06713616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racemic ketamine
Description: Ketamine will be given intravenously. Per FDA guidance, the max dose of ketamine will be 60mg per day, with a total lifetime limit of 8 doses. Ketamine will be infused over 40 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spravato (Esketamine)
Description: Spravato® (Esketamine) will be given intranasally. For esketamine, the dose will be between 56 and 84mg, according to the FDA label for the drug. Allowances will be made for patients who have difficulty tolerating these doses to be dosed at 28mg in subsequent treatment sessions.
Study: NCT06713343

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airways
Description: The 172 patients who will be admitted for elective surgery will be divided into two groups as Group L and Group R by computer-assisted randomization method. Patients in Group L will be ventilated with a classical laryngeal mask airways (cLMA) stored at 10 °C to 12 °C (low temperatures), while patients in Group R will be ventilated with a classical laryngeal mask airways (cLMA) stored at 22 °C to 25 °C (room temperatures).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airways
Description: The 172 patients who will be admitted for elective surgery will be divided into two groups as Group L and Group R by computer-assisted randomization method. Patients in Group L will be ventilated with a classical laryngeal mask airways (cLMA) stored at 10 °C to 12 °C (low temperatures), while patients in Group R will be ventilated with a classical laryngeal mask airways (cLMA) stored at 22 °C to 25 °C (room temperatures).
Study: NCT06714253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RXRG001
Description: Circular ribonucleic acid encoding human aquaporin 1 encapsulated in a lipid nanoparticle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RXRG001
Description: Circular ribonucleic acid encoding human aquaporin 1 encapsulated in a lipid nanoparticle

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (saline)
Study: NCT05974072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The pharmacological treatment will be individualised according to pain intensity, contraindications and the appearance of adverse effects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAINDOC Program
Description: The PAINDOC Program consists in:~* Therapeutic education: The therapeutic education block consists of two parts: an education session called Empowered Relief (ER) and two pain neuroscience education (NDT) sessions.~* Psychotherapy: The psychotherapy part consists of one group session of one hour, face-to-face and with groups of up to 15 people, given by the psychologist of the pain unit.~* Mindfulness Meditation: The Mindfulness Meditation consists of one group session of one hour, face-to-face and with groups of up to 15 people. These are given by a nurse from the pain unit. T~* Therapeutic exercise: The therapeutic exercise module consists of three sessions of one hour each, face-to-face, with small groups of between 6 and 10 patients, and given by the physiotherapist of the pain unit.
Study: NCT05971225

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: remote monitoring only
Description: remote monitoring only can replace in-office device monitoring
Study: NCT05179031

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: First Reference product (dextrose, containing 25 g of carbohydrates)
Description: Reference dextrose solution containing 25 g of available carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Second Reference product (dextrose, containing 25 g of carbohydrates)
Description: Reference dextrose solution containing 25 g of available carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Third Reference product (dextrose, containing 25 g of carbohydrates)
Description: Reference dextrose solution containing 25 g of available carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High protein tube feed
Description: Nutritional product containing 25 g of available carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High-protein tube feed with additional amino acid
Description: Nutritional product containing 25 g of available carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral Nutritional Supplement for diabetes patients
Description: Nutritional product containing 25 g of available carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral Nutritional Supplement for diabetes patients (new formula)
Description: Nutritional product containing 25 g of available carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: ONS for disease related malnutrition
Description: Nutritional product containing 25 g of available carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Plantbased ONS for disease related malnutrition
Description: Nutritional product containing 25 g of available carbohydrates
Study: NCT04898907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG-3777 (Therapeutic Dose)
Description: Arms assigned to this intervention will receive 2 mg/kg, IV, Fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG-3777 (Supra-therapeutic Dose)
Description: Arms assigned to this intervention will receive 6 mg/kg, IV, Fasted

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arms assigned to this intervention will receive normal saline, IV, Fasted

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Hydrochloride
Description: Arms assigned to this intervention will receive 400 mg, Oral, Fasted
Study: NCT06224699

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Toothpaste Product
Description: Use of toothpaste with or without sodium carbonate at 67%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toothpaste Product
Description: Use of toothpaste with or without sodium carbonate at 67%
Study: NCT05602779

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: tVNS and Phone App Program
Description: Participants will have both the Neuvana Xen Device and the full version of our program's phone app. They will use the device and full app access for 30 days.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Enhanced Treatment as Usual
Description: Participants will have access to our program's phone app so the can play the game and will be called weekly to complete risk assessments.
Study: NCT05971225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote monitoring only
Description: remote monitoring only can replace in-office device monitoring
Study: NCT05966051

Intervention type: BEHAVIORAL
Intervention: Educational interventions
Description: The educational interventions will consist in:
Study: NCT06518005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlifidase
Description: Imlifidase: single administration (dose is confidential), Lyophilized powder for concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNT0003
Description: GNT0003: single administration 5E+12 VG/kg, Sterile concentrate for solution for infusion
Study: NCT05367427

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Heat treated postbiotic Bifidobacterium Longum consumption
Description: Regular consumption in breakfast of heat treated postbiotic B. longum

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT04623190

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-List Control
Description: -Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREVENT tool
Description: -PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREVENT tool
Description: -PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
Study: NCT05380219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual task strength training
Description: strength training and dual task

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dual task strength training
Description: strength training and dual task
Study: NCT06059417

Intervention type: OTHER
Group type: OTHER
Intervention: 2x2 inch piece of 3M microfoam adhesive
Description: A 2x2 inch piece of 3M microfoam adhesive will be applied to the medial aspect of the subject's upper arm.~The adhesive will remain in place for 48 hours at which time an investigator will remove the adhesive and assess the study area. A numerical value will be assigned based on the Cutaneous Irritancy Scoring System (CISS). The study site will be compared to the contra-lateral upper extremity at the end of the 48 hour period.
Study: NCT05155579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M - single vial formulation
Description: Adjuvanted malaria vaccine in a single vial formulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M - single vial formulation
Description: Adjuvanted malaria vaccine in a single vial formulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M - single vial formulation
Description: Adjuvanted malaria vaccine in a single vial formulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M - single vial formulation
Description: Adjuvanted malaria vaccine in a single vial formulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M - single vial formulation
Description: Adjuvanted malaria vaccine in a single vial formulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M - single vial formulation
Description: Adjuvanted malaria vaccine in a single vial formulation
Study: NCT05742711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Primary Relief
Description: Continuous neurostimulation with a set of pre-assigned stimulation parameters.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Primary Relief - Sham Device
Description: Standard treatment with the application of sham device shall be followed with additional analgesics available if necessary.
Study: NCT06285708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged exposure
Description: PE therapy is a manualized cognitive behavioral therapy consisting of imaginal exposure (repeated recounting of the most disturbing traumatic memory) followed by processing thoughts and feelings related to the imaginal experience; in-vivo exposure (approaching trauma-related situations); psychoeducation about PTSD; and controlled breathing training. Between sessions, participants listen to audio recordings of the imaginal recounting daily and complete in-vivo exercises. Typically, PE is delivered weekly for 10-12, 90-minutes sessions. For this study, participants will complete daily 60-minute sessions for 10 consecutive weekdays during a 2-week period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged exposure
Description: PE therapy is a manualized cognitive behavioral therapy consisting of imaginal exposure (repeated recounting of the most disturbing traumatic memory) followed by processing thoughts and feelings related to the imaginal experience; in-vivo exposure (approaching trauma-related situations); psychoeducation about PTSD; and controlled breathing training. Between sessions, participants listen to audio recordings of the imaginal recounting daily and complete in-vivo exercises. Typically, PE is delivered weekly for 10-12, 90-minutes sessions. For this study, participants will complete daily 60-minute sessions for 10 consecutive weekdays during a 2-week period.
Study: NCT05155579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M - two vial formulation
Description: Adjuvanted malaria vaccine in a double vial formulation
Study: NCT05088226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib combined with Chidamide.
Description: Drug: modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide .~Day -15 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -14 # Ruxolitinib 70mg bid; Day -13 # Ruxolitinib 70mg bid; Day -12 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -11 # Ruxolitinib 70mg bid; Day-10# Cytarabine 4g/m2/day CI , Ruxolitinib 60mg bid; Day- 9# Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once; Day- 7# Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid; Day-6# Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once; Day-4# Cyclophosphamide 1.8 g/m2/day CI,Ruxolitinib 20mg bid; Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid; Day-2# Ruxolitinib 5mg bid, Chidamide 30 mg/day; Day-1# Ruxolitinib 5mg qd;
Study: NCT06090552

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Letter, AD, PREPARE, reminders, healthcare navigator
Description: Letter, AD, PREPARE, reminders, healthcare navigator
Study: NCT05155579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licensed vaccine - Measles-rubella
Description: Licensed vaccine part of the EPI vaccination schedule

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed vaccine - Measles-rubella
Description: Licensed vaccine part of the EPI vaccination schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licensed vaccine - Yellow fever
Description: Licensed vaccine part of the EPI vaccination schedule

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed vaccine - Yellow fever
Description: Licensed vaccine part of the EPI vaccination schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licensed vaccine - Pentavalent (diphtheria, tetanus, pertussis, hepatitis B and Hib)
Description: Licensed vaccine part of the EPI vaccination schedule

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed vaccine - Pentavalent (diphtheria, tetanus, pertussis, hepatitis B and Hib)
Description: Licensed vaccine part of the EPI vaccination schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licensed vaccine - Oral Polio Vaccine (OPV)
Description: Licensed vaccine part of the EPI vaccination schedule

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed vaccine - Oral Polio Vaccine (OPV)
Description: Licensed vaccine part of the EPI vaccination schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licensed vaccine - Rotavirus
Description: Licensed vaccine part of the EPI vaccination schedule

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed vaccine - Rotavirus
Description: Licensed vaccine part of the EPI vaccination schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licensed vaccine - Pneumococcal vaccine
Description: Licensed vaccine part of the EPI vaccination schedule
Study: NCT05974800

Intervention type: BEHAVIORAL
Intervention: Emergency department caregivers interview
Description: The interview focuses on several parts of the emergency care process: The first part is regarding the actions that are executed during an emergency department visit. We will establish which actions are executed and why. The second part is regarding the suspected outcome for the patient. The third part will be about any potential improvements to the emergency care process for the patient.
Study: NCT05001737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emapalumab
Description: Emapalumab iv infusion
Study: NCT05640817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline 400 mg SR tablets
Description: a nonspecific phosphodiesterase inhibitor, was first considered in the treatment of peripheral vascular diseases

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin with standard hydration with normal saline
Description: chemotherapy
Study: NCT01131247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab + bendamustine
Description: Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.